TVTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.06%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $2,164,946.05

Travere Therapeutics Insider Trading History Chart

Travere Therapeutics Share Price & Price History

^$19.06

▲ +0.88 (4.84%)

As of 11/26/2024 07:11 PM ET

Days: 30 | 90 | 365

This Bull Market Indicator called NVDA at $116

From WealthPress | Ad

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Travere Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/25/2024	Sandra Calvin	CAO	Sell	12,090	$18.30	$221,247.00	54,927
10/4/2024	Gary A Lyons	Director	Sell	40,000	$14.73	$589,200.00	51,000
9/30/2024	Jeffrey A Meckler	Director	Sell	40,000	$14.06	$562,400.00	81,000
9/9/2024	Christopher R Cline	CFO	Sell	2,490	$11.52	$28,684.80	74,595
9/9/2024	Eric M. Dube	CEO	Sell	21,125	$11.52	$243,360.00	361,975
9/9/2024	Jula Inrig	Insider	Sell	2,191	$11.52	$25,240.32	62,633
9/9/2024	William E. Rote	SVP	Sell	4,387	$11.52	$50,538.24	84,455
9/4/2024	Christopher R Cline	CFO	Sell	514	$9.51	$4,888.14	70,335
4/11/2024	Christopher R Cline	CFO	Sell	54	$6.74	$363.96	70,849
2/1/2024	Christopher R Cline	CFO	Sell	3,818	$8.53	$32,567.54	70,903
2/1/2024	Eric M. Dube	CEO	Sell	19,122	$8.70	$166,361.40	350,600
2/1/2024	Peter Heerma	Insider	Sell	4,195	$8.53	$35,783.35	99,503
2/1/2024	Sandra Calvin	CAO	Sell	2,820	$8.53	$24,054.60	52,017
2/1/2024	William E. Rote	SVP	Sell	4,764	$8.71	$41,494.44	80,720
1/23/2024	Christopher R Cline	CFO	Sell	853	$9.07	$7,736.71	49,721
1/23/2024	Elizabeth E. Reed	SVP	Sell	2,062	$8.96	$18,475.52	56,034
1/23/2024	Eric M. Dube	CEO	Sell	7,873	$8.96	$70,542.08	234,722
1/23/2024	Peter Heerma	Insider	Sell	1,559	$9.07	$14,140.13	78,698
1/23/2024	Sandra Calvin	CAO	Sell	910	$9.07	$8,253.70	41,337
1/3/2024	Jula Inrig	Insider	Sell	2,069	$9.48	$19,614.12	35,688
10/3/2023	Peter Heerma	Insider	Sell	3,091	$8.25	$25,500.75	80,257
9/5/2023	Christopher R Cline	CFO	Sell	457	$14.71	$6,722.47	50,574
9/5/2023	Eric M. Dube	CEO	Sell	4,455	$14.71	$65,533.05	242,595
9/5/2023	William E. Rote	SVP	Sell	1,815	$14.71	$26,698.65	61,173
5/10/2023	Christopher R Cline	CFO	Sell	455	$16.59	$7,548.45	51,031
5/10/2023	Elizabeth E. Reed	SVP	Sell	825	$16.59	$13,686.75	56,611
5/10/2023	Sandra Calvin	CAO	Sell	436	$16.59	$7,233.24	42,369
4/11/2023	Christopher R Cline	CFO	Sell	47	$21.49	$1,010.03	51,486
2/1/2023	Christopher R Cline	CFO	Sell	1,588	$21.75	$34,539.00	51,533
2/1/2023	Elizabeth E. Reed	SVP	Sell	2,590	$22.25	$57,627.50	57,436
2/1/2023	Eric M. Dube	CEO	Sell	8,196	$22.25	$182,361.00	237,150
2/1/2023	Peter Heerma	Insider	Sell	1,779	$21.75	$38,693.25	82,069
2/1/2023	Sandra Calvin	CAO	Sell	1,671	$21.75	$36,344.25	43,165
1/24/2023	Christopher R Cline	CFO	Sell	852	$21.90	$18,658.80	32,871
1/24/2023	Eric M. Dube	CEO	Sell	6,442	$21.50	$138,503.00	147,846
1/24/2023	Peter Heerma	Insider	Sell	1,550	$21.90	$33,945.00	63,598
1/24/2023	Sandra Calvin	CAO	Sell	905	$21.90	$19,819.50	35,028
1/24/2023	William E. Rote	SVP	Sell	2,062	$21.50	$44,333.00	42,376
1/5/2023	Eric M. Dube	CEO	Sell	5,625	$20.75	$116,718.75	154,288
1/4/2023	Jula Inrig	Insider	Sell	2,051	$20.75	$42,558.25	17,949
10/4/2022	Peter Heerma	Insider	Sell	3,042	$25.68	$78,118.56	65,148
9/13/2022	Sandra Calvin	CAO	Sell	349	$28.00	$9,772.00	35,933
5/11/2022	Steve Aselage	Director	Sell	2,575	$21.92	$56,444.00	146,919
5/11/2022	William E. Rote	SVP	Sell	1,563	$21.71	$33,932.73	43,672
5/10/2022	Laura Clague	CFO	Sell	825	$21.51	$17,745.75	37,030
5/10/2022	Sandra Calvin	CAO	Sell	436	$21.51	$9,378.36	36,178
1/31/2022	Elizabeth E. Reed	SVP	Sell	1,350	$27.40	$36,990.00
1/31/2022	Eric M. Dube	CEO	Sell	4,813	$27.40	$131,876.20
1/31/2022	Laura Clague	CFO	Sell	1,238	$27.40	$33,921.20
1/31/2022	Peter Heerma	Insider	Sell	1,125	$27.40	$30,825.00
1/31/2022	Sandra Calvin	CAO	Sell	798	$26.51	$21,154.98
1/24/2022	Eric M. Dube	CEO	Sell	7,873	$24.98	$196,667.54
1/24/2022	Laura Clague	CFO	Sell	2,063	$24.98	$51,533.74
1/24/2022	Sandra Calvin	CAO	Sell	934	$24.58	$22,957.72
1/24/2022	William E. Rote	SVP	Sell	1,875	$24.98	$46,837.50
1/11/2022	Elizabeth E. Reed	SVP	Sell	5,000	$27.40	$137,000.00
1/11/2022	Laura Clague	CFO	Sell	7,500	$27.40	$205,500.00
1/4/2022	Eric M. Dube	CEO	Sell	4,832	$30.43	$147,037.76

Has Trump Finally Gone Too Far?

From Insiders Exposed | Ad

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

SEC Filings (Institutional Ownership Changes) for Travere Therapeutics (NASDAQ:TVTX)

Institutional Buying and Selling by Quarter

Travere Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/20/2024	Virtu Financial LLC	21,500	$0.30M	0.0%	N/A	0.028%
11/16/2024	Geode Capital Management LLC	1,731,045	$24.22M	0.0%	+3.9%	2.218%
11/15/2024	Barclays PLC	168,768	$2.36M	0.0%	-9.4%	0.216%
11/15/2024	Y Intercept Hong Kong Ltd	28,217	$0.40M	0.0%	-70.4%	0.036%
11/15/2024	XTX Topco Ltd	14,205	$0.20M	0.0%	-73.8%	0.018%
11/15/2024	Two Sigma Advisers LP	720,400	$10.08M	0.0%	+30.2%	0.923%
11/15/2024	State Street Corp	2,736,696	$38.29M	0.0%	-22.0%	3.506%
11/15/2024	Quarry LP	7,500	$0.11M	0.0%	N/A	0.010%
11/15/2024	Parkman Healthcare Partners LLC	1,086,067	$15.19M	1.9%	+12.0%	1.392%
11/15/2024	Jacobs Levy Equity Management Inc.	1,590,377	$22.25M	0.1%	-15.8%	2.038%
11/15/2024	HighVista Strategies LLC	147,233	$2.06M	0.7%	-32.9%	0.189%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	4,037	$56K	0.0%	-88.6%	0.005%
11/14/2024	Bellevue Group AG	31,000	$0.43M	0.0%	N/A	0.040%
11/14/2024	PDT Partners LLC	264,273	$3.70M	0.3%	+10.7%	0.339%
11/14/2024	Walleye Capital LLC	488,453	$6.83M	0.0%	+70.1%	0.626%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	163,175	$2.28M	0.0%	-8.7%	0.209%
11/14/2024	Zurcher Kantonalbank Zurich Cantonalbank	19,969	$0.28M	0.0%	+20.9%	0.026%
11/14/2024	Acuta Capital Partners LLC	19,000	$0.27M	0.2%	N/A	0.024%
11/14/2024	Healthcare of Ontario Pension Plan Trust Fund	843,300	$11.80M	0.0%	+37.1%	1.080%
11/13/2024	Finepoint Capital LP	1,782,267	$24.93M	1.8%	+0.3%	2.283%
11/13/2024	FMR LLC	147,416	$2.06M	0.0%	+27.5%	0.189%
11/13/2024	The Manufacturers Life Insurance Company	47,045	$0.66M	0.0%	+61.6%	0.060%
11/12/2024	Charles Schwab Investment Management Inc.	567,409	$7.94M	0.0%	-0.2%	0.727%
11/9/2024	Intech Investment Management LLC	20,226	$0.28M	0.0%	N/A	0.026%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	525,381	$7.35M	0.0%	+11.2%	0.673%
11/7/2024	Quest Partners LLC	3,871	$54K	0.0%	-73.0%	0.005%
11/6/2024	Oppenheimer & Co. Inc.	48,139	$0.67M	0.0%	N/A	0.063%
11/5/2024	Aigen Investment Management LP	12,180	$0.17M	0.0%	N/A	0.016%
11/4/2024	Los Angeles Capital Management LLC	27,951	$0.39M	0.0%	-67.0%	0.037%
10/29/2024	Emerald Advisers LLC	1,960,659	$27.43M	1.1%	+19.8%	2.563%
10/29/2024	Emerald Mutual Fund Advisers Trust	1,185,709	$16.59M	0.9%	+26.0%	1.550%
10/28/2024	Oak Ridge Investments LLC	55,339	$0.77M	0.1%	-3.9%	0.072%
10/28/2024	Rice Hall James & Associates LLC	94,736	$1.33M	0.1%	+24.4%	0.124%
10/25/2024	China Universal Asset Management Co. Ltd.	14,712	$0.21M	0.0%	+64.5%	0.019%
10/24/2024	Nisa Investment Advisors LLC	4,846	$68K	0.0%	-16.1%	0.006%
10/24/2024	Semanteon Capital Management LP	36,699	$0.51M	0.3%	N/A	0.048%
10/23/2024	Assenagon Asset Management S.A.	1,374,522	$19.23M	0.0%	-37.9%	1.806%
10/23/2024	Hennion & Walsh Asset Management Inc.	36,604	$0.51M	0.0%	-9.5%	0.048%
10/11/2024	Creative Planning	23,938	$0.34M	0.0%	+4.3%	0.031%
10/8/2024	CWM LLC	4,999	$70K	0.0%	+158.5%	0.007%
10/7/2024	Diversified Trust Co	11,532	$0.16M	0.0%	N/A	0.015%
9/20/2024	Healthcare of Ontario Pension Plan Trust Fund	615,000	$5.06M	0.0%	+203.0%	0.804%
9/16/2024	Cubist Systematic Strategies LLC	346,068	$2.85M	0.0%	-0.6%	0.452%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	35,377	$0.29M	0.1%	N/A	0.046%
8/16/2024	Forefront Analytics LLC	13,317	$0.11M	0.1%	+10.2%	0.017%
8/15/2024	Millennium Management LLC	2,949,335	$24.24M	0.0%	+33.9%	3.856%
8/15/2024	AQR Capital Management LLC	74,069	$0.61M	0.0%	+55.7%	0.097%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	35,377	$0.29M	0.1%	N/A	0.046%
8/14/2024	Squarepoint Ops LLC	15,580	$0.13M	0.0%	-35.3%	0.020%
8/14/2024	Cubist Systematic Strategies LLC	346,068	$2.85M	0.0%	-0.6%	0.452%
8/14/2024	Point72 DIFC Ltd	21,315	$0.18M	0.0%	N/A	0.028%
8/14/2024	Bank of Montreal Can	75,919	$0.63M	0.0%	N/A	0.099%
8/14/2024	DRW Securities LLC	11,598	$95K	0.0%	N/A	0.015%
8/14/2024	ProShare Advisors LLC	14,457	$0.12M	0.0%	-21.5%	0.019%
8/14/2024	Profund Advisors LLC	33,836	$0.28M	0.0%	-63.1%	0.044%
8/13/2024	Sei Investments Co.	14,226	$0.12M	0.0%	N/A	0.019%
8/12/2024	XTX Topco Ltd	54,262	$0.45M	0.0%	+110.5%	0.071%
8/12/2024	Hsbc Holdings PLC	48,994	$0.40M	0.0%	-8.4%	0.064%
8/12/2024	E Fund Management Co. Ltd.	11,071	$91K	0.0%	-60.6%	0.014%
8/9/2024	Renaissance Technologies LLC	2,203,814	$18.12M	0.0%	-23.0%	2.895%
8/8/2024	Federated Hermes Inc.	41,717	$0.34M	0.0%	N/A	0.055%
8/8/2024	Rice Hall James & Associates LLC	76,174	$0.63M	0.0%	+3.8%	0.100%
8/6/2024	Quest Partners LLC	14,336	$0.12M	0.0%	+240.6%	0.019%
8/6/2024	Emerald Advisers LLC	1,637,146	$13.46M	0.6%	-6.4%	2.150%
8/6/2024	Emerald Mutual Fund Advisers Trust	941,265	$7.74M	0.4%	-29.1%	1.236%
8/6/2024	Acadian Asset Management LLC	144,901	$1.19M	0.0%	+202.6%	0.190%
8/6/2024	Los Angeles Capital Management LLC	84,817	$0.70M	0.0%	-9.2%	0.111%
8/5/2024	Arizona State Retirement System	19,176	$0.16M	0.0%	-7.1%	0.025%
8/1/2024	Rhumbline Advisers	125,660	$1.03M	0.0%	+17.4%	0.165%
7/29/2024	Principal Financial Group Inc.	10,288	$85K	0.0%	-44.7%	0.014%
7/29/2024	Panagora Asset Management Inc.	90,881	$0.75M	0.0%	N/A	0.119%
7/26/2024	Bank of New York Mellon Corp	264,816	$2.18M	0.0%	+18.3%	0.348%
7/18/2024	Assenagon Asset Management S.A.	2,214,099	$18.20M	0.0%	+912.5%	2.908%
7/17/2024	Oak Ridge Investments LLC	57,584	$0.47M	0.0%	-12.7%	0.076%
7/12/2024	SG Americas Securities LLC	16,884	$0.14M	0.0%	N/A	0.022%
7/11/2024	Talbot Financial LLC	63,546	$0.52M	0.1%	N/A	0.083%
5/16/2024	California State Teachers Retirement System	74,883	$0.58M	0.0%	-5.0%	0.098%
5/16/2024	Jacobs Levy Equity Management Inc.	1,124,685	$8.67M	0.0%	-34.5%	1.477%
5/16/2024	Bayesian Capital Management LP	22,935	$0.18M	0.0%	N/A	0.030%
5/15/2024	Price T Rowe Associates Inc. MD	31,009	$0.24M	0.0%	+10.5%	0.041%
5/15/2024	Affinity Asset Advisors LLC	125,000	$0.96M	0.1%	N/A	0.164%
5/14/2024	EntryPoint Capital LLC	4,101	$32K	0.0%	N/A	0.005%
5/14/2024	Healthcare of Ontario Pension Plan Trust Fund	203,000	$1.57M	0.0%	-68.0%	0.267%
5/10/2024	Acadian Asset Management LLC	47,881	$0.37M	0.0%	N/A	0.063%
5/10/2024	Vanguard Group Inc.	6,265,829	$48.31M	0.0%	+13.6%	8.233%
5/9/2024	State Board of Administration of Florida Retirement System	19,235	$0.15M	0.0%	-7.5%	0.025%
5/8/2024	ProShare Advisors LLC	18,421	$0.14M	0.0%	+9.2%	0.024%
5/8/2024	Russell Investments Group Ltd.	184,623	$1.42M	0.0%	+79.2%	0.243%
5/3/2024	GSA Capital Partners LLP	58,601	$0.45M	0.0%	N/A	0.077%
5/1/2024	Oak Ridge Investments LLC	65,926	$0.51M	0.1%	+13.3%	0.087%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	50,178	$0.39M	0.0%	+8.1%	0.066%
4/29/2024	China Universal Asset Management Co. Ltd.	14,652	$0.11M	0.0%	+68.6%	0.019%
4/24/2024	Assenagon Asset Management S.A.	218,680	$1.69M	0.0%	-13.9%	0.287%
4/23/2024	Rice Hall James & Associates LLC	73,400	$0.57M	0.0%	+4.5%	0.096%
4/17/2024	Hennion & Walsh Asset Management Inc.	40,790	$0.31M	0.0%	+14.4%	0.054%
4/5/2024	Los Angeles Capital Management LLC	93,417	$0.72M	0.0%	N/A	0.123%
3/21/2024	Healthcare of Ontario Pension Plan Trust Fund	635,277	$5.71M	0.0%	N/A	0.835%
2/26/2024	Virtu Financial LLC	19,498	$0.18M	0.0%	N/A	0.026%
2/20/2024	Quarry LP	4,500	$40K	0.0%	-55.0%	0.006%
2/15/2024	Parkman Healthcare Partners LLC	1,018,812	$9.16M	1.3%	+76.4%	1.356%

Data available starting January 2016

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $19.06

$18.19

$19.12

50 Day Range

MA: $16.85

$13.65

$19.85

52 Week Range

Now: $19.06

$5.12

$20.33

Volume

1,751,036 shs

Average Volume

1,398,739 shs

Market Capitalization

$1.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Who are the company insiders with the largest holdings of Travere Therapeutics?: Travere Therapeutics' top insider investors include:
Eric M Dube (CEO)
Peter Heerma (Insider)
William E Rote (SVP)
Jeffrey A Meckler (Director)
Christopher R Cline (CFO)
Jula Inrig (Insider)
Elizabeth E Reed (SVP)
Sandra Calvin (CAO)
Gary A Lyons (Director)
Learn More about top insider investors at Travere Therapeutics.
Who are the major institutional investors of Travere Therapeutics?: Travere Therapeutics' top institutional shareholders include:
State Street Corp — 3.51%
Emerald Advisers LLC — 2.56%
Finepoint Capital LP — 2.28%
Geode Capital Management LLC — 2.22%
Jacobs Levy Equity Management Inc. — 2.04%
Assenagon Asset Management S.A. — 1.81%
Learn More about top institutional investors of Travere Therapeutics stock.
Which institutional investors are selling Travere Therapeutics stock?: In the previous quarter, TVTX stock was sold by these institutional investors:
Assenagon Asset Management S.A.
State Street Corp
Jacobs Levy Equity Management Inc.
HighVista Strategies LLC
Y Intercept Hong Kong Ltd
Los Angeles Capital Management LLC
XTX Topco Ltd
Point72 Asia Singapore Pte. Ltd.
In the previous year, company insiders that have sold Travere Therapeutics company stock include:
Eric M Dube (CEO)
Peter Heerma (Insider)
William E Rote (SVP)
Jeffrey A Meckler (Director)
Christopher R Cline (CFO)
Jula Inrig (Insider)
Elizabeth E Reed (SVP)
Sandra Calvin (CAO)
Gary A Lyons (Director)
Learn More investors selling Travere Therapeutics stock.
Which institutional investors are buying Travere Therapeutics stock?: In the last quarter, TVTX stock was bought by institutional investors including:
Jane Street Group LLC
Emerald Advisers LLC
Emerald Mutual Fund Advisers Trust
Healthcare of Ontario Pension Plan Trust Fund
Walleye Capital LLC
Two Sigma Advisers LP
Parkman Healthcare Partners LLC
Geode Capital Management LLC